28277099|t|CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis
28277099|a|Phagocytes, such as macrophages and microglia, are key effector cells in the pathophysiology of multiple sclerosis (MS). It is widely accepted that they instigate and promote neuroinflammatory and neurodegenerative events in MS. An increasing amount of studies indicate that Siglec-1, also known CD169, is a marker for activated phagocytes in inflammatory disorders. In this study, we set out to define how CD169(+) phagocytes contribute to neuroinflammation in MS. CD169 - diphtheria toxin receptor (DTR) mice, which express human DTR under control of the CD169 promoter, were used to define the impact of CD169(+) cells on neuroinflammation. Flow cytometry and immunohistochemistry were utilized to determine the expression and distribution of CD169. We show that CD169 is highly expressed by lesional and circulating phagocytes in MS and experimental autoimmune encephalomyelitis (EAE). Our data further indicate that CD169 represents a selective marker for early activated microglia in MS and EAE lesions. Depletion of CD169(+) cells markedly reduced neuroinflammation and ameliorated disease symptoms in EAE - affected mice. Our findings indicate that CD169(+) cells promote neuroinflammation. Furthermore, they suggest that CD169(+) phagocytes play a key role in the pathophysiology of MS. Hence, targeting CD169(+) phagocytes may hold therapeutic value for MS.
28277099	0	5	CD169	T116,T129,T192	C0142251
28277099	11	17	marker	T201	C0005516
28277099	22	28	highly	T080	C0205250
28277099	29	39	pathogenic	T169	C0543483
28277099	40	50	phagocytes	T025	C0031307
28277099	54	72	multiple sclerosis	T047	C0026769
28277099	73	83	Phagocytes	T025	C0031307
28277099	93	104	macrophages	T025	C0024432
28277099	109	118	microglia	T025	C0206116
28277099	128	142	effector cells	T025	C0312740
28277099	150	165	pathophysiology	T169	C0031847
28277099	169	187	multiple sclerosis	T047	C0026769
28277099	189	191	MS	T047	C0026769
28277099	207	215	accepted	T080	C1272684
28277099	226	235	instigate	T078	C1548602
28277099	240	247	promote	T169	C0205245
28277099	248	265	neuroinflammatory	T169	C0333348
28277099	270	287	neurodegenerative	T049	C0027746
28277099	288	294	events	T051	C0441471
28277099	298	300	MS	T047	C0026769
28277099	305	315	increasing	T169	C0442808
28277099	316	322	amount	T081	C1265611
28277099	326	333	studies	T062	C2603343
28277099	348	356	Siglec-1	T116,T129,T192	C0142251
28277099	369	374	CD169	T116,T129,T192	C0142251
28277099	381	387	marker	T201	C0005516
28277099	392	401	activated	T169	C0205177
28277099	402	412	phagocytes	T025	C0031307
28277099	416	438	inflammatory disorders	T047	C1290884
28277099	448	453	study	T062	C2603343
28277099	480	488	CD169(+)	T116,T129,T192	C0142251
28277099	489	499	phagocytes	T025	C0031307
28277099	500	510	contribute	T052	C1880177
28277099	514	531	neuroinflammation	T046	C0021368
28277099	535	537	MS	T047	C0026769
28277099	539	544	CD169	T116,T129,T192	C0142251
28277099	547	572	diphtheria toxin receptor	T116,T129,T192	C0058402
28277099	574	577	DTR	T116,T129,T192	C0058402
28277099	579	583	mice	T015	C0025929
28277099	599	604	human	T016	C0086418
28277099	605	608	DTR	T116,T129,T192	C0058402
28277099	615	622	control	T080	C0243148
28277099	630	635	CD169	T028	C1420266
28277099	636	644	promoter	T114,T123	C0086860
28277099	651	655	used	T169	C1524063
28277099	670	676	impact	T080	C4049986
28277099	680	688	CD169(+)	T116,T129,T192	C0142251
28277099	689	694	cells	T025	C0007634
28277099	698	715	neuroinflammation	T046	C0021368
28277099	717	731	Flow cytometry	T059	C0016263
28277099	736	756	immunohistochemistry	T060	C0021044
28277099	762	770	utilized	T169	C1524063
28277099	788	798	expression	T045	C0597360
28277099	819	824	CD169	T116,T129,T192	C0142251
28277099	839	844	CD169	T116,T129,T192	C0142251
28277099	848	854	highly	T080	C0205250
28277099	855	864	expressed	T045	C0597360
28277099	868	876	lesional	T033	C0221198
28277099	881	892	circulating	T040	C1516559
28277099	893	903	phagocytes	T025	C0031307
28277099	907	909	MS	T047	C0026769
28277099	914	955	experimental autoimmune encephalomyelitis	T050	C0014072
28277099	957	960	EAE	T050	C0014072
28277099	967	971	data	T078	C1511726
28277099	994	999	CD169	T116,T129,T192	C0142251
28277099	1000	1010	represents	T052	C1882932
28277099	1023	1029	marker	T201	C0005516
28277099	1040	1059	activated microglia	T025	C0206116
28277099	1063	1065	MS	T047	C0026769
28277099	1070	1073	EAE	T050	C0014072
28277099	1074	1081	lesions	T033	C0221198
28277099	1083	1092	Depletion	T169	C0333668
28277099	1096	1104	CD169(+)	T116,T129,T192	C0142251
28277099	1105	1110	cells	T025	C0007634
28277099	1120	1127	reduced	T080	C0392756
28277099	1128	1145	neuroinflammation	T046	C0021368
28277099	1150	1161	ameliorated	T080	C0439856
28277099	1162	1169	disease	T047	C0012634
28277099	1170	1178	symptoms	T184	C1457887
28277099	1182	1185	EAE	T050	C0014072
28277099	1188	1196	affected	T169	C0392760
28277099	1197	1201	mice	T015	C0025929
28277099	1207	1215	findings	T033	C0243095
28277099	1216	1224	indicate	T078	C0392360
28277099	1230	1238	CD169(+)	T116,T129,T192	C0142251
28277099	1245	1252	promote	T169	C0205245
28277099	1253	1270	neuroinflammation	T046	C0021368
28277099	1303	1311	CD169(+)	T116,T129,T192	C0142251
28277099	1312	1322	phagocytes	T025	C0031307
28277099	1323	1327	play	T033	C0600138
28277099	1334	1338	role	T077	C1705810
28277099	1346	1361	pathophysiology	T169	C0031847
28277099	1365	1367	MS	T047	C0026769
28277099	1376	1385	targeting	T169	C1521840
28277099	1386	1394	CD169(+)	T116,T129,T192	C0142251
28277099	1395	1405	phagocytes	T025	C0031307
28277099	1415	1426	therapeutic	T169	C0302350
28277099	1427	1432	value	T169	C0457083
28277099	1437	1439	MS	T047	C0026769